miR-21 Expression in Grade I, II, and III Breast Cancer


  • Juwita - Master of Biomedical Sciences, Faculty of Medicine, North SumatraUniversity, Medan Departments of Biochemistry, Faculty of Medicine, Syiah Kuala University, Banda Aceh
  • Henny E.S. Ompusunggu Master of Biomedical Sciences, Faculty of Medicine, North SumatraUniversity, Medan Departments of Cell and Molecular Biology, Faculty of Medicine, HKBP Nommensen University, Medan
  • Donny Nauphar Departments of Biochemistry, Faculty of Medicine, Swadaya Gunung Jati University, Cirebon
  • Sumondang M. Pardede Department of Anatomical Pathology Dr H. Adam Malik Hospital
  • Hadyanto Lim Departments of Pharmacology, Faculty of Medicine, Methodist Indonesia University, Medan Department Biomolecular, Faculty of Medicine, Methodist Indonesia University, Medan
  • Yahwardiah Siregar Master of Biomedical Sciences, Faculty of Medicine, North SumatraUniversity, Medan Departments of Biochemistry, Faculty of Medicine, North Sumatra University, Medan


Background: Breast cancer is the second largest cancer in the world.The gold standard for breast cancer diagnosis and prognosis is grade assessment (mitotic, nuclear pleiomorphism, tubular formation), based on breast tissue histopathology. However, this assessment has limitation in that it is subjective and semi quantitative. A genetic biomarker known as


Aguas F, Martins A, Gomes TP, de Sousa M, Silva DP (2005). Portuguese Menopause Society and Portuguese Gynaecology Society: Prophylaxis approach to a symptomatic post menopausal women: breast cancer. Maturitas, 52: S23-31.

Bitomsky N, Bohm M, Klempnauer KH (2004). Transformation suppressor protein Pdcd4 interferes with JNK mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene, 23: 7484–7493.

Calin GA and Croce CM (2006). MicroRNA-Cancer Connection: The Beginning of a New Tale. Cancer Res,66: 7390-7394.

Chen PS, Su JL, Hung MN (2012). Dysregulation of MicroRNAs in cancer. Review. Journal of Biomedical Science, 19 (90): 1-8.

Cho WCS (2007). OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer, 6: 60–66.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2010). Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127: 2893–2917.

Fernandez SV and Russo J (2009). Estrogen and Xenoestrogens in Breast Cancer. Toxicol Pathol, 38: 110-122.

Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem,283 (2): 1026–1033.

Hulka BS and Moorman PG (2001). Breast Cancer: Hormones and other risk factors. Maturitas, 38: 103-116.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65: 7065–7070.

Jansen AP, Camalier CE, Colburn NH (2005). Epidermal Expression of The Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis. Cancer Res, 65: 6034-6041.

Kementerian Kesehatan Indonesia (2013). Profil Kesehatan Indonesia Tahun 2012.http://www.depkes.go.id. Diakses Maret 2014.

Key TJ (2003). Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women. Endogenous Hormones and Breast Cancer Collaborative Group. J Natl Cancer Inst, 95: 1218-1226.

Kluttig A and Pokrzywniak AS (2009). Established and Suspected Risk Factor in Breast Cancer Aetiology. Breast Care, 4: 82-87.

Lee JA, Lee HY, Lee ES, Kim I, and Bae JW (2011). Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J Breast Cancer,14 (4): 269-275.

Li Q, Wang X, Wu X, Rui Y, Liu W, Wang J, Wang X (2007). Daxx Cooperates with the Axin/HIPK2/p53 Complex to Induce Cell Death. Cancer Res,67: 66-74.

Lin L, Ozaki T, Takada Y, Kageyama H, Nakamura Y, Hata A, Zhang JH (2005). topors, a p53 and topoi somerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage. Oncogene, 24: 3385–3396.

Malhotra GK, Zhao X, Band H, Band V (2010). Histological, molecular and functional subtypes of breast cancers. Cancer Biology & Therapy, 10(10): 955-960.

McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R (2003). Adiposity and SexHormones in Postmenopausal Breast Cancer Survivors, J.Clin. Oncol., 21: 1961-1966.

Moumen A, Masterson P, O’Connor MJ, Jackson SP (2005). hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage. Cell, 123: 1065–1078.

Papagiannakopoulos T, Shapiro A, Kosik KS (2008). MicroRNA-21 Targets a Network of Key Tumor Suppressive Pathways in Glioblastoma Cells. Cancer Res.,68: 8164-8172.

Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L (2009). High miR-21 expression in breast cancer associated with poor diseasefree survival in early stage disease and high TGF β1. Breast Cancer Res Treat, 117: 131–140.

Rakha EA, Reis Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res., 12 (207): 1-12.

Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, Garber J (2006). 17-Beta estradiol induces transformation and tumorigenesis in human breast epithelial cells. The FASEB Journal Research Communication, 20: 1622-1634.

Tavassoli FA and Devilee P (2003). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. France: IARC Press Lyon: 18-19.

Verderio P (2005). Quality control for histological grading in breast cancer: an italian experience. Pathological, 97: 1-6.

Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14: 2348-2360.

Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, Colburn NH (2001). A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kB or ODC transactivation. Oncogene, 20: 669-676.